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Background: 6-Mercaptopurine (6-MP) and its prodrug azathioprine (AZA) have proven efficacy in the 
treatment of Crohn disease (CD). The immunosuppressive properties of AZA/6-MP are mediated by the 
intracellular metabolism of 6-MP into its active metabolites, 6-thioguanine nucleotides (6TGN) and 6-
methylmercaptopurine (6-MMP). Preliminary studies have suggested that the red blood cell concentration of 
6TGN (RBC 6TGN) is a potential guide to therapy. The aims of the study were to evaluate the RBC 6TGN 
concentrations in adult patients with CD under long-term AZA/6-MP therapy and to correlate it with response to 
treatment and haematological parameters.  
Methods: Twenty-eight CD patients treated for at least 3 months with AZA/6-MP were prospectively studied. 
Patients were separated into three main groups: group 1 (n = 19), corresponding to quiescent CD receiving AZA 
(dose: 2.05 ± 0.4 mg/kg/day for a mean of 28.6 ± 25 months) or 6-MP (dose: 1.4 ± 01 mg/kg/day for a mean of 
7.5 ± 3.5 months) alone; group 2 (n = 6), corresponding to quiescent CD treated by AZA (dose: 2.14 ± 0.5 
mg/kg/day for a mean of 29.5 ± 22 months) with oral steroids; and group 3 (n = 3), corresponding to active CD 
on AZA (dose: 1.94 ± 0.6 mg/kg/day for a mean of 31.3 ± 35 months) as the only treatment. An assessment was 
also made by merging groups 1 and 2 forming a larger group of patients (n = 25) defined by clinical remission 
and groups 2 and 3 forming a larger group of patients (n = 9), non-complete responders with AZA/6-MP alone. 
Crohn disease index activity (CDAI), blood samples for full blood count and differential white cell count and 
measurement of RBC 6TGN and 6-MMP concentrations were evaluated at inclusion and at 6 months (n = 17). 
RBC 6TGN were measured using high performance liquid chromatography (HPLC) on heparinized blood.  
Results: The baseline characteristics of the three groups of patients were similar. There was no significant 
difference among the three groups of patients regarding the dose and the duration of immunosuppressive 
treatment. There was no significant difference between groups according to various parameters tested. 
Particularly, the median RBC 6TGN concentration at inclusion was similar in the three groups of patients (166 
(105-688), 183 (90-261) and 160 (52-194) pmol/8 × 108 RBC, respectively). The majority of patients had no 
detectable level of 6-MMP metabolite, except for 3 patients. There was also no difference between merging 
groups. Furthermore, there was no significant correlation between RBC 6TGN concentrations and the various 
biological parameters tested except for the mean erythrocyte volume. At 6 months, all patients of group 1 
remained in remission and median RBC 6TGN concentration remained stable. No side effects were observed.  
Conclusions: There is, contrary to preliminary studies, a broad overlap in RBC 6TGN levels as well as for 
haematological parameters in patients in remission or not and responders or not to AZA/6-MP therapy. This 
suggests, beside a variability in the metabolism of these drugs, the existence of complex mechanisms of action. 
Nevertheless, beside the use of RBC 6TGN determination to confirm compliance to therapy, this dosage could 
be useful in non-responding patients, allowing, in absence of leukopenia, to increase the dose of AZA/6-MP 
safely. 
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6-Mercaptopurine (6-MP) and its prodrug azathioprine (AZA) have proven efficacy in the treatment of Crohn 
disease (CD). A meta-analysis of all placebo-controlled trials of AZA/ 6-MP treatment for CD reported overall 
response rates of 56% and 67% for treatment of active disease and remission maintenance indications (1). These 
drugs have now been recognized as having a major role in the treatment of steroid dependent CD, eliminating the 
need for corticosteroids in about 75% of patients, with a median response time of 3-4 months (2, 3). 
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Furthermore, these immunosuppressants have also been shown to improve the quality of life (4). However, 
potential complications of treatment occur in 15% of patients (5). Moreover, 25%-35% of the patients do not 
respond to AZA/6-MP treatment even after several months, raising the possibility that altered drug metabolism 
effects efficacy. Therapeutic drug monitoring during treatment with AZA/6-MP has the potential to address these 
problems. The immunosuppressive properties of AZA/6-MP are considered to be mediated mainly by the 
intracellular metabolism into its active 6-thioguanine nucleotides (6TGN) (5). 6TGN have a long half-life 
resulting in slow accumulation in red blood cells (RBCs) and other body tissues and the need for prolonged 
treatment to reach steady-state levels. These metabolites seem thus to be appropriate candidates for such 
monitoring. However in CD, only a recently published paper in paediatric series of CD indicates that monitoring 
based on red blood cell concentration of 6TGN (RBC 6TGN) is a potential guide to therapy (6). 
The aim of this study was to evaluate the RBC 6TGN concentrations in adult patients with CD on long-term 
therapy with AZA or 6-MP and to correlate it with response to treatment and haematological parameters. 
Patients and Methods 
Patients 
The study was performed between March 1999 and December 1999. The study design is shown in Fig. 1. 
Eligible patients were all patients with CD seen during this period and treated for at least 3 months by AZA/6-
MP. Twenty-eight patients with CD (19 females, 9 males), mean age 37 years (range, 24-58), were included in 
this study. The diagnosis of CD was made using the clinical, morphological and histological criteria of Gower-
Rousseau et al. (7). The reason for immunosuppressive treatment had been in all cases corticosteroid dependent 
CD, except in 2 patients with an early severe postoperative recurrence. The corticosteroid dependency was 
defined as previously reported (8), either by two successive relapses during the 2 months following steroid 
discontinuation, or by two successive relapses at dose tapering after successful treatment of flare-up with 
steroids. The activity of CD was determined at inclusion by the Crohn Disease Activity Index (CDAI). Twenty-
five patients had quiescent CD (CDAI < 150) and 3 patients had active disease (CDAI: median score, 210; range, 
200-395) despite immunosuppressive treatment. The patients were separated into three main groups at inclusion 
(Table I). Patients with quiescent CD were separated into two groups: group 1 corresponding to 19 patients 
treated with AZA (n = 17) or 6-MP (n = 2) as the only treatment; group 2 corresponding to 6 patients treated by 
AZA and methylprednisolone (mean dose: 13 mg/day ± 10). Group 3 included the 3 patients with active 
symptomatic CD. These 3 patients were on AZA as the only treatment. The baseline characteristics of the three 
groups of patients are summarized in Table II. An assessment was also made by merging groups 1 and 2, 
forming a larger group of patients (n = 25) defined by clinical remission, and groups 2 and 3, forming a larger 
group of patients (n = 9), non-complete responders with AZA or 6-MP alone (Table I). 
 
Fig. 1. Design of the study. 
 
 
Table I. Definition of the groups of patients at inclusion 
Group 1 Quiescent CD with AZA/6-MP alone (complete responders) 
Group 2 Quiescent CD with AZA + oral steroids 
Group 3 Active CD under AZA as only treatment 
Group 1 + 2 Patients in clinical remission 
Group 2 + 3 Non-complete responders with AZA alone 
 
In addition to clinical assessment, blood samples were taken for total full blood count and differential white cell 
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count and measurement of RBC 6TGN concentrations. The total RBC 6TGN concentration measurement was 
based on the conversion of 6TGN to the free 6-thioguanine base, assayed by high performance liquid 
chromatography (HPLC) on heparinized blood according to the method of Lennard & Singleton (9). Two quality 
control samples at 119 and 299 pmol/8 × 108 were analysed during each run. The intra-day coefficients of 
variation were 4.1% (110 ± 4.6pmol/ 8 × 108 RBCs) and 4.5% (304 ± 13.7 pmol/8 × 108 RBCs), respectively, for 
n = 6. The interday coefficients of variation were 8% (120 ± 9.5 pmol/8 × 108 RBCs) and 6.9% (300  ± 20.8 
pmol/8 × 108 RBCs), respectively, for n = 17. The sensitivity for 6TGN reached 5 pmol/8 × 108 RBCs. The '6-
methymercaptopurine like' (6-MMP) metabolite was detected on the same chromatogram with a sensitivity of 1 
nmol/8 × 108 RBCs. 
The assessment was performed firstly by comparing RBC 6TGN concentrations and haematological parameters 
between groups. Secondly, according to previous published RBC 6TGN data, we tried to validate a discriminant 
RBC 6TGN level by comparing the response to treatment in subgroups of patients divided according to the RBC 
6TGN levels (230 pmol/8 × 108 RBCs (10), 250 pmol/8 × 108 RBCs (11)). 
Seventeen patients of 28 included (group 1 = 10; group 2 = 4; group 3 = 3) were re-evaluated at 6 months for 
disease activity and RBC 6TGN concentrations. 
Statistical analysis 
Comparative statistics were carried out using Student t test or Mann-Whitney U test as appropriate. Correlations 
between the various parameters were assessed by Spearman test. Values of P < 0.05 were considered to indicate 
statistical significance. 
Results 
The baseline characteristics of the three patient groups were similar (Table II). There was no significant 
difference among the three groups of patients regarding the dose and duration of immunosuppressive treatment. 
There was no significant difference between groups according to various parameters tested (Table III). 
Particularly, the median RBC 6TGN concentrations at inclusion are similar in the three groups of patients. There 
was also no difference between group 1 and group 2 + 3 (166 pmol/ 8 × 108 RBCs (range, 105-688) and 167 
pmol/8 × 108 RBCs (range, 52-261), respectively), and between group 1 + 2 and group 3 (167 pmol/8 × 108 
RBCs (range, 90-688) and 160 pmol/8 × 108 RBCs (range, 52-194), respectively). Furthermore, there was no 
significant correlation between RBC 6TGN concentrations and the various biological parameters tested except 
for the mean erythrocyte volume (MCV) which was higher in patients on AZA (Table IV). 
The number of patients having a RBC 6TGN level higher than the two discriminant levels proposed in the 
literature were 6 and 8 for 250 and 230 pmol/8 × 108 RBCs, respectively. The proportion of patients as complete 
or non-complete responders on AZA/6-MP, according to these discriminant levels, are shown in Table V. No 
significant differences were found between patients above or below the discriminant levels. A low level of 6-
MMP was noted in 2 patients of group 1 and 1 patient of group 2 (8.5, 6.0, and 4.2 nmol/8 × 108 RBCs, 
respectively). 
At 6 months, all patients in group 1 (n = 10) remained in remission (CDAI < 150) with no modification (except 1 
patient, see below) of AZA/6-MP therapy. RBC 6TGN levels remained relatively stable except in the patient 
with the highest concentration at inclusion (688 pmol/8 × 108 RBCs) in whom the dose of AZA had to be 
decreased (Fig. 2). The median (range) coefficient of variation over this 6-month period was 4% (3.6%-40.7%). 
In group 2 (n = 4), 1 patient had a flare-up at 5 months. At this time the level of RBC 6TGN concentration had 
decreased from 235 to 103 pmol/ 8 × 108 RBCs, despite the absence of treatment modification. The other 
patients were still in remission with the same dose of AZA and 2 of them were weaned from steroids (Table VI). 
The follow up of the 3 patients in group 3 is shown on Table VΠ. No side effects were observed. 
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Fig. 2. RBC 6TGN concentrations at inclusion and at 6 months in quiescent CD treated by AZA/6-MP alone 
(patients n = 10 of group 1). The RBC 6TGN levels remained relatively stable. The median (range) coefficient of 
variation over this 6 months period was 4% (3.6%-40.7%). 
 
 
Table II. Baseline characteristics of the patients at inclusion 
Variable Group 1 (n = 19) Group 2 (n = 6) Group 3 (n = 3) 
Sex (M/F) 4/15 1/5 0/3 
Age at entry (years) (mean ± s, range) 36.8 ± 10.4 (24-58) 43.6  ± 8.5 (37-58) 32 ± 3.5 (30-36) 
Duration of disease (years) (mean ± s, range) 10.2 ± 5.9 (1-23) 12.6  ± 7.7 (2-22) 10.6 ± 2 (9-13) 
Duration of remission (months) (median, range) 10 (2-84) 7.5 (3-24) NA 
Disease site (no. of patients) 
Ileum 2   
Ileocolon 10 1 2 
Colon 7 5 1 
Azathioprine* 
Duration (months) (mean ± s, range) 28.6 ± 25 (3-84) 29.5 ± 22 (3-60) 31.3 ± 35 (5-72) 
Dose (mg/kg/day) (mean ± s, range) 2.05 ± 0.4 (1.35-2.8) 2.14 ± 0.5 (1.5-3) 1.94 ± 0.6 (1.88-2) 
6-MP† 
Duration (months) (mean ± s, range) 7.5 ± 3.5 (5-10)   
Dose (mg/kg/day) (mean ± s, range) 1.4 ± 0.1 (1.35-1.5)   
NA =  not applicable. 
* n =17 
† n = 2 
 
Table III.  Biological profiles of the patients at inclusion 
Variable Group 1 (n = 19) Group 2 (n = 6) Group 3 (n = 3) 
RBC 6TGN (pmol/8 × 108 RBCs) (median, range) 166 (105-688) 183 (90-261) 160 (52-194) 
MCV (µ3) (mean ± s, range) 93 ± 8 (74-104) 96 ± 3.5 (90-100) 83 ± 7 (77-91) 
Leukocyte count (× 103/ml) (mean ± s, range) 6.4 ± 1.81 (3.34-9.17) 9.6 ± 2.7 (5.9-10.3) 5.9 ± 0.8 (5.1-6.7) 
Neutrophils count (× 103/ml) (mean ± s, range) 4.6 ± 1.1 (2.2-7.7) 7.1 ± 1.5 (5.1-8.6) 4.3 ± 1.1 (3.0-5.2) 
Relative neutrophilia (%) (mean ± s, range) 67 ± 15 (15-84) 74 ±b7.5 (66-84) 71.5 ± 15 (59-78) 
Lymphocyte count (×103 /ml) (mean ± s, range) 10.8 ± 4.5 (6-22) 15.6 ± 5 (10-22) 9 ± 3.5 (5-11) 
Relative lymphocytosis (%) (mean ± s, range) 17.8 ± 7.7 (6.2-33.8) 16 ± 5.6 (9.0-21) 15.9 ± 6.9 (8.7-22.5) 
Study variables 
 
Table IV. Correlations (r) between RBC 6TGN concentrations, treatment and haematological parameters at 
inclusion 
Variable r P 
AZA/6-MP dose (mg/kg/day) 0.020 0.917 
AZA/6-MP duration 0.060 0.758 
Leukocyte count 0.243 0.241 
Neutrophil count 0.180 0.387 
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Relative neutrophilia 0.168 0.42 
Lymphocyte count -0.029 0.889 
Relative lymphocytosis -0.332 0.104 
MCV 0.375 0.048 
 
Table V. Proportion of patient responders and non-complete responders according to the two RBC 6TGN 
discriminant levels proposed in the literature (10, 11) 
Patients RBC 6TGN 
> 250 pmol/8 × 108 RBCs 
RBC 6TGN 
< 250 pmol/8 × 108 RBCs 
RBC 6TGN 
> 230 pmol/8 × 108 RBCs 
RBC 6TGN 
< 230 pmol/8 × 108 RBCs 
Complete responders 
(group 1 = 19) 
5/6 14/22 6/8 13/20 
Non-complete responders 
(group 2 + 3 = 9) 
1/6 8/22 2/8 7/20 
 
Table VI. Follow up at 6 months for patients of group 2 
Patient RBC 6TGN at inclusion  
(pmol/8 × 108) 
RBC 6TGN at 6 months 
(pmol/8 × 108) 
Comments 
MB 261 190 Steroid withdrawal at 3 months 
JPL 235 NA* Flare-up at 5 months treated by anti-TNF 
LP 200 224 Steroid withdrawal at 2 months 
ND 100 139 Quiescent CD with same dose of steroid 
* Not available (RBC 6TGN at time of flare-up (5 months): 103 pmol/8 × 108). 
 
Table VII. Follow up at 6 months for patients of group 3 
Patient RBC 6TGN 
(pmol/8 × 108 RBCs) 
at inclusion 
RBC 6TGN 
(pmol/8 × 108 RBCs) 
at 6 months 
Comments 
HT 52 200 AZA increased from 1.8 to 2.5 mg/kg/day and 
ciprofloxacin added at inclusion. In remission 2 months 
later with AZA alone 
NP 160 95 AZA increased from 2.5 to 3 mg/kg/day and oral 
budesonide added at inclusion. In remission 6 months 
later with AZA alone 
JF 194 235 AZA increased from 1.6 to 2 mg/kg/day and 
methylprednisolone added at inclusion. In remission 6 
months later with AZA alone 
 
Discussion 
We evaluated in the present study the monitoring of long-term treatment with AZA/6-MP by RBC 6TGN 
concentrations in patients with CD. The data showed a broad overlap in RBC 6TGN concentrations as well as 
haematological parameters in patients in remission or not and responders or not to AZA/6-MP. Accordingly, in 
this relatively small population, we could not confirm the previously proposed discriminant RBC 6TGN levels 
between responders and non-responders to AZA/6-MP. 
AZA/6-MP are immunosuppressive drugs that are effective in the treatment of inflammatory bowel disease. 
These drugs have now been recognized as major drugs in the treatment of steroid dependent and chronic active 
CD. A recently published meta-analysis of the therapeutic trials of AZA in CD showed a significant efficacy 
both in active disease and in maintenance of remission (1). In these two situations, the efficacy correlated with 
the cumulative dose administered, depending on the dose and duration of the treatment. When using an 
appropriate dose, which is at least 2 mg/kg/day for AZA and 1.5 mg/kg/day for 6-MP, and waiting enough time 
for judgement of efficacy (at least 3-4 months), 60%-70% of patients show a significant clinical response while 
25%-35% of patients do not respond even after several months. In a recent pilot study of 18 non-responders after 
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a mean time of 11 months at a mean dose of 2 mg/kg/day, the increase of AZA to 2.5-3 mg/kg/day brought up a 
significant clinical response in 78% of the patients (12). In that study, the increase in AZA dosage was decided 
empirically, simply checking that it was not associated with major leukopenia. A previous study with 6-MP in 
refractory CD had showed that the clinical response correlated with the development of a relative leukopenia and 
neutropenia (below 5000 leukocytes/ ml) (13). However, in another well-conducted recent prospective study, this 
correlation was not confirmed (14). Furthermore, the concentration of 6-MP itself seems to be of no value in 
monitoring the treatment, probably because this substance is inactive and has a very short half-life (1-2 h) in 
plasma (15). The considerable variability in optimal dosage of 6-MP is probably related to the large variability in 
its metabolization by the three major pathways. After rapid non-enzymatic conversion of AZA to 6-MP, three 
enzymes compete to metabolize 6-MP: xanthine oxidase, which converts 6-MP to the inactive metabolite 6-
thiouracic; thiopurine methyltransferase (TPMT), which converts 6-MP to 6-MMP (unclear metabolic activity); 
and hypoxanthine phosphoribosyl transferase followed by inosine monophosphate dehydrogenase and guanosine 
monophosphate synthetase, which convert 6-MP to the active metabolites 6TGN. Thus, RBC 6TGN 
concentration appears to be a potential candidate for the monitoring of therapeutic efficacy of AZA/ 6-MP. 
Pharmacological studies showing a prolonged half-life and a slow accumulation of 6TGN in the erythrocyte have 
been challenged by a recent study demonstrating that a steady state of RBC 6TGN concentration was obtained 
after only 2 weeks, even following classical oral treatment (14). 
The RBC 6TGN concentration monitoring in patients treated with AZA/6-MP has been used in leukaemia and 
transplantation (16-19). In the treatment of children with acute lymphoblastic leukaemia treated with 6-MP, the 
RBC 6TGN concentration associated with efficacy was greater than 275 pmol/8 × 108 RBCs (16) while 
significant leukopenia was induced at concentration higher than 1000 pmol/8 × 108 RBCs (17). Therefore, the 
therapeutic window for RBC 6TGN in leukaemia seems to be 275-1000 pmol/8 × 108 RBCs, while in 
transplantation lower levels (100-200 pmol/ 8 × 108 RBCs) are proposed but have not been clearly associated 
with a better response to treatment (19). 
In CD very few data have been published. The RBC 6TGN target levels remain controversial. A study by Cuffari 
et al. performed in adolescent CD with steroid dependent or steroid refractory CD and treated with 6-MP for 
more than 4 months showed a negative correlation between disease activity and RBC 6TGN levels (6). In a 
further work published as an abstract, a RBC 6TGN greater than 250 pmol/8 × 108 RBCs was proposed as a 
target level (11). Such a discriminant level was also suggested by an another team in a recently published work 
(10). The first study (6), has been criticized for its non-complete prospective design and the absence of clear 
definition of steroid dependent and refractory patients (20). In contrast, our study is fully prospective and was 
performed on well-defined subgroups of patients. In this condition our results do not confirm a significant 
correlation between RBC 6TGN and response to AZA/6-MP. Indeed, median RBC 6TGN levels were similar, 
around 160 pmol/8 × 108 RBCs, in patients in remission with AZA/6-MP alone and in patients still needing 
steroids to control their disease or patients with active disease despite AZA/6-MP. This absence of correlation as 
well as a relatively low RBC 6TGN level in responders to AZA/6-MP was also observed by Sandborn et al. in 
patients with steroid dependent disease (14). In this study a steady level of RBC 6TGN, around 160 pmol/8 × 108 
RBCs, was already obtained after 2 weeks of treatment and remained stable for another 16 weeks. We also found 
that the level of RBC 6TGN remained stable even over 6 months, in patients in which the oral dose of 
AZA/6TGN was not changed. In a few patients, however, RBC 6TGN levels may vary significantly despite the 
absence of change in drug dosage. Interestingly, in 1 of our patients in remission under AZA and steroids RBC 
6TGN levels decreased from 235 to 103 pmol/ 8 × 108 RBCs while AZA dosage remained unchanged. However, 
we can not exclude a lack of compliance therapy. Concomitantly, this patient experienced a relapse suggesting 
that in an individual patient a target level could be determined for efficacy. As shown earlier, however, this level 
seems particular to a given patient and can not be applied to the others. Obviously, in a larger population, as 
recently published, a statistically significant discriminant level may appear for the whole group (10). However, 
this must not occult the fact that many patients are responders to the treatment with lower RBC 6 TGN levels 
and that this 'discriminant level' is probably not very relevant from a clinical point of view, and has not to be 
considered as a universal target. 
In our study, no significant correlation was found either between response to therapy and various haematological 
parameters. Particularly, as with Sandborn et al. (14), we could not confirm the association between response to 
AZA/ 6-MP and relative leukopenia. Analysing the various biological parameters together, the only significant 
correlation was between RBC 6TGN and MCV. This indicates that the MCV may to some extent reflect the 
accumulation of active metabolites in the erythrocyte (21). 
No side effect of AZA/6-MP was observed in our patients over 6 months. This may be explained by the fact that 
all patients were already at inclusion under long-term therapy; the majority of patients with potential side effects 
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having already stopped the treatment prior to the study, which was thus not specifically designed for the 
investigation of side effects. As far as toxicity is concerned, Cuffari et al. proposed an association with high level 
of 6-MMP metabolite (6). The majority of our patients had no 6-MMP detected level and the only 3 patients in 
which it was detected had relatively low levels compared to Cuffari et al.'s patients. It must be noted that the 
sensitivity of our test was lower than the one of Lennard & Singleton (9). Therefore, some lower levels in the 
range 0.1-1 nmol/8 × 108 RBCs may have been missed. However, according to Cuffari et al. (6), these levels do 
not seen to correlate with significant side effects. The relatively low concentration of RBC 6TGN and the 
absence of 6-MPP in patients non-responding to AZA (group 3) allowed us to increase the dosage of AZA with 
safety. Indeed, in these patients the increase of a mean of 0.5 mg/kg/day was not associated with any 
haematological complication over a 6-month period. Quite surprisingly, although, in 2 patients this increase in 
AZA dosage was followed by an increased RBC 6TGN concentration, in the 3rd patient a significant decrease 
was observed. 
In conclusion, this work shows, contrary to preliminary studies, a broad overlap of RBC 6TGN levels as well as 
haematological parameters in patients in remission or not and responders or not to AZA/6-MP therapy. This 
suggests, beside a variability in the metabolism of these drugs, the existence of complex mechanisms of action. 
Nevertheless, beside the use of RBC 6TGN to confirm compliance to therapy, this dosage could be useful in 
non-responding patients, allowing, in the absence of leukopenia, to increase the dose of AZA/6-MP with safety. 
The specific utility of this dosage beside direct evaluation of methylation capacity (either genetic or biological) 
should be assessed in prospective studies. 
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